Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherNeuropharmacology

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors

Marek Samochocki, Anja Höffle, Andreas Fehrenbacher, Ruth Jostock, Jürgen Ludwig, Claudia Christner, Martin Radina, Marion Zerlin, Christoph Ullmer, Edna F.R. Pereira, Hermann Lübbert, Edson X. Albuquerque and Alfred Maelicke
Journal of Pharmacology and Experimental Therapeutics March 20, 2003, DOI: https://doi.org/10.1124/jpet.102.045773
Marek Samochocki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anja Höffle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Fehrenbacher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth Jostock
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jürgen Ludwig
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Christner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Radina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marion Zerlin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Ullmer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edna F.R. Pereira
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hermann Lübbert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edson X. Albuquerque
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfred Maelicke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading
PDF extract preview

This is a PDF-only article. The first page of the PDF of this article appears above.

Next
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 381 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 381, Issue 2
1 May 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherNeuropharmacology

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors

Marek Samochocki, Anja Höffle, Andreas Fehrenbacher, Ruth Jostock, Jürgen Ludwig, Claudia Christner, Martin Radina, Marion Zerlin, Christoph Ullmer, Edna F.R. Pereira, Hermann Lübbert, Edson X. Albuquerque and Alfred Maelicke
Journal of Pharmacology and Experimental Therapeutics March 20, 2003, DOI: https://doi.org/10.1124/jpet.102.045773

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherNeuropharmacology

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors

Marek Samochocki, Anja Höffle, Andreas Fehrenbacher, Ruth Jostock, Jürgen Ludwig, Claudia Christner, Martin Radina, Marion Zerlin, Christoph Ullmer, Edna F.R. Pereira, Hermann Lübbert, Edson X. Albuquerque and Alfred Maelicke
Journal of Pharmacology and Experimental Therapeutics March 20, 2003, DOI: https://doi.org/10.1124/jpet.102.045773
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Antipsychotic-VMAT2 Inhibitor Synergy: Schizophrenia Models
  • Rescue Pharmacology on Disease-Related GRIN Variants
  • Obesity thwarts preconditioning in TBI
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics